At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 target
Drug / intervention
temsirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jan 27, 2003·Updated Jun 26, 2018
In Brief
A Phase 2 clinical trial evaluating temsirolimus for Brain and Central Nervous System Tumors. Completed, enrolled 49 participants across 10 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have malignant glioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2001
First PostedJan 2003
Primary CompletionMay 2006
Study CompletionDec 2007
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartAug 27, 2001
Primary CompletionMay 4, 2006
Study CompletionDec 15, 2007
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 23.4 years ago
Interventions
temsirolimusdrug